US regulatory status: approved.
pharma · Dry Eye · Conjunctivitis, Allergic · ALDX
Aldeyra Therapeutics
Aldeyra Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US HQ
2004 Founded
14 Employees
Public company Type
ALDX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
- Founded
- 2004
- Employees
- 14
- Programs
- 26
- Drugs
- 12
- Patents
- 38
Aldeyra Therapeutics pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Aldeyra Therapeutics drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.
-
Development asset linked to Aldeyra Therapeutics in public FDA and regional records.